N

    Nautilus Biotechnology Inc (NAUT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.97
    +0.09 (+9.79%)

    Market Cap: $112.71M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    86%(19/22)
    Avg Surprise
    -9.03%
    Streak
    19 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.15+0.0%
    60d ago$-0.15+0.0%
    30d ago$-0.15+0.0%
    7d ago$-0.15+0.0%
    Current$-0.15
    Revenue Consensus
    $200000
    Range$200000 - $200000
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.07
    Range$-0.10 - $-0.04
    2 analysts
    Revenue Consensus
    $300000
    Range$300000 - $300000
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.07---
    Sep 26EST
    		-$-0.15---
    Jun 26
    		$-0.11$-0.14+21.43%Beat+8.3%
    Mar 26
    		$-0.12$-0.14+14.29%Beat+7.7%
    Dec 25
    		$-0.11$-0.15+29.03%Beat+21.4%
    Sep 25
    		$-0.11$-0.15+26.67%Beat+15.4%
    Jun 25
    		$-0.12$-0.14+14.29%Beat+14.3%
    Mar 25
    		$-0.13$-0.14+7.14%Beat+13.3%
    Dec 24
    		$-0.14$-0.15+6.67%Beat+0.0%
    Sep 24
    		$-0.13$-0.17+23.53%Beat+0.0%
    Jun 24
    		$-0.14$-0.16+12.50%Beat-7.7%
    Mar 24
    		$-0.15$-0.16+6.25%Beat-25.0%
    Dec 23
    		$-0.14$-0.14+0.00%Beat-27.3%
    Sep 23
    		$-0.13$-0.16+18.75%Beat-18.2%
    Jun 23
    		$-0.13$-0.16+18.75%Beat-8.3%
    Mar 23
    		$-0.12$-0.17+29.41%Beat+7.7%
    Dec 22
    		$-0.11$-0.15+26.67%Beat+15.4%
    Sep 22
    		$-0.11$-0.15+26.67%Beat+8.3%
    Jun 22
    		$-0.12$-0.17+29.41%Beat+36.8%
    Mar 22
    		$-0.13$-0.16+18.75%Beat+62.9%
    Dec 21
    		$-0.13$-0.13+0.00%Beat-550.0%
    Sep 21
    		$-0.12$-0.10-20.00%Miss-1100.0%
    Jun 21
    		$-0.19$-0.07-171.43%Miss-
    Mar 21
    		$-0.35$-0.08-337.50%Miss-
    Dec 20
    		$-0.02N/AN/ABeat-
    Sep 20
    		$-0.01N/AN/ABeat-
    Jun 20
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.16EV/EBITDA-2.00x
    Price/FCF-2.38xFCF Yield-41.95%
    Profitability
    Profit Margin0.00%Operating Margin-8296.00%
    ROE-36.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.14xQuick Ratio10.14x
    Trading Statistics
    Beta0.87Avg Volume733.64K
    52-Week High$4.3152-Week Low$0.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.91
    SMA 20$0.90
    SMA 50$1.39
    SMA 200$2.18
    EMA 10$0.92
    EMA 20$0.99
    EMA 50$1.35
    EMA 200$1.85

    MACD

    Line: -0.13Signal: -0.18Hist: 0.04

    ADX

    ADX: 40.5+DI: 19.4-DI: 24.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down36.0
    PSAR$0.87

    Bollinger Bands

    Upper Band$0.97
    Lower Band$0.83
    %B Position1538%(Upper)
    Band Width0.99

    RSI (14-Day)

    Neutral
    42.0

    Momentum Oscillators

    Stoch %K54.3
    Stoch %D49.4
    Williams %R-8.8
    ROC (10d)10.4%
    Momentum0.09
    CCI (20d)98.1
    MFI (14d)56.1

    Volatility Measures

    ATR (14d)$0.09(9.1%)
    StdDev (20d)0.03
    Hist Vol72.0%(High)

    Volume Flow

    VWAP$0.95
    OBV-14.5M
    AD Line-24.0M
    CMF (20d)-0.256

    Volume Metrics

    Avg Vol (20d)709.1K
    Vol Ratio1.1x
    VWMA (20d)$0.91

    Pivot Points

    R3$0.96
    R2$0.94
    R1$0.91
    Pivot Point$0.89
    S1$0.86
    S2$0.84
    S3$0.82

    Advanced Oscillators

    TSI-38.48
    Ultimate Osc44.4
    KST-298.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$190,000$0$0$0$0$0$9.60M$0$0$0$8.21M$0
    Cost of Revenue$15,000$0$1.59M$1.62M$0$0$6.35M$0$0$0$1.59M$0
    Gross Profit$175,000$0$-1,588,000$-1,619,000$0$0$-6,353,000$0$0$0$-1,590,000$0
    Operating Expenses$15.94M$16.12M$13.84M$15.47M$17.10M$18.84M$19.98M$19.10M$20.79M$21.61M$20.00M$19.07M
    R&D$9.61M$9.71M$10.92M$9.61M$10.39M$11.54M$12.82M$12.29M$12.44M$12.93M$12.47M$12.00M
    SG&A$6.33M$6.42M$5.85M$5.87M$6.70M$7.31M$7.16M$6.81M$8.35M$8.68M$7.54M$7.08M
    Operating Income$-15,763,000$-16,124,000$-15,424,000$-15,472,000$-17,097,000$-18,844,000$-19,980,000$-19,100,000$-20,789,000$-21,607,000$-20,001,000$-19,075,000
    Interest Income$1.31M$1.44M$1.65M$1.90M$2.08M$2.23M$2.43M$2.67M$2.80M$2.88M$3.03M$3.20M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-14,469,000$-14,697,000$-13,781,000$-13,574,000$-15,033,000$-16,613,000$-17,594,000$-16,446,000$-18,010,000$-18,730,000$-17,024,000$-15,878,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-14,469,000$-14,697,000$-13,781,000$-13,574,000$-15,033,000$-16,613,000$-17,594,000$-16,446,000$-18,010,000$-18,730,000$-17,024,000$-15,878,000
    EBITDA$-14,480,000$-14,731,000$-12,193,000$-11,955,000$-15,919,000$-17,760,000$-18,971,000$-18,231,000$-22,073,000$-20,767,000$-19,086,000$-18,220,000
    EBIT$-15,776,000$-16,139,000$-13,781,000$-13,574,000$-17,113,000$-18,844,000$-19,980,000$-19,120,000$-20,808,000$-21,607,000$-20,057,000$-19,075,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NAUT

    News

    Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest

    Nautilus Biotechnology (NASDAQ:NAUT) experienced a substantial 56.9% surge in short interest in July, reaching 2.27 million shares, representing 3.0% of its shares and a 2.7 days-to-cover ratio. The stock opened at $0.88, below its moving averages, despite the company beating EPS and revenue estimates in its latest quarterly report. A major shareholder significantly reduced their position, while analysts hold a consensus "Hold" rating with an average price target of $4.00.

    MarketBeat•8/18/26•
    Somewhat-Bearish

    Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A

    Perceptive Advisors and its related entities have filed an updated 13D/A, disclosing a 9.1% beneficial ownership in Nautilus Biotechnology, Inc. (NAUT), totaling 11,634,211 shares. This ownership is primarily held by Perceptive Life Sciences Master Fund, Ltd. and C2 Life Sciences LLC, with Perceptive Advisors LLC and Joseph Edelman sharing voting and dispositive power as investment managers. The percentage is based on 127,255,223 shares of Nautilus common stock outstanding as of July 24, 2026.

    Stock Titan•8/14/26•
    Neutral

    NAUT|Nautilus Biotechnology Inc|Price:0.977|Chg%:-0.053

    Nautilus Biotechnology Inc (NAUT) closed at $0.977, experiencing a 5.15% decline. Analysts rate NAUT as a "Strong Buy" with a target price indicating a 284.62% upside. The company is a development-stage life sciences firm focused on proteomics, aiming to democratize access to the human proteome with its analysis system and reagent kits.

    TradingKey•8/2/26•
    Bearish

    Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT

    The article provides a basic financial overview page for Nautilus Biotechnology, Inc. (NASDAQ:NAUT) on TradingView. It indicates that the market is closed, with no trades, and points to various financial data sections such as statements, statistics, dividends, earnings, and segments. The content primarily outlines the navigational structure of the financial information available for the company on the platform.

    TradingView•7/31/26•
    Neutral

    Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and ...

    Nautilus Biotechnology Inc (NAUT) has announced a strategic shift of R&D resources towards its proteoform application, showing strong customer interest and initial revenue from collaborations. While facing a net loss of $14.5 million and needing further fundraising, the company highlights its unique proteoform assay capabilities as a key competitive advantage. They plan to expand their proteoform portfolio and sales team, expecting substantial commercial opportunities and increased instrument demand.

    Yahoo Finance UK•7/29/26•
    Neutral

    Frequently Asked Questions About NAUT

    Does NAUT pay dividends?
    Nautilus Biotechnology Inc (NAUT) does not currently pay a regular dividend.
    What is NAUT's market cap?
    Nautilus Biotechnology Inc (NAUT) has a market capitalization of $112.71M with a current stock price of $0.97.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In